Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection (Tailwind)

Key Inclusion Criteria: ≥ 18 years old Body mass index (BMI) of ≥ 18 kg/m2 Evidence of bronchiectasis per CT Evidence of chronic pulmonary Pseudomonas aeruginosa infection Willing to undergo sputum induction procedures at designated study visits, and willing to provide expectorated sputum samples at all other timepoints (for subjects who are able to expectorate) FEV1 ≥ 35% of predicted normal [per Global Lung Function Initiative (GLI) standards] at Screening For Cohort A: have not received chronic inhaled antipseudomonal antibiotics regimen for at least 3 months prior to Visit 1 For Cohort B: have received chronic inhaled antipseudomonal antibiotics regimen for at least 3 months prior to Visit 1 Key Exclusion Criteria: Abnormal vital signs at Screening History of lung transplantation History of cystic fibrosis History of α1-antitrypsin deficiency History of primary or acquired immunodeficiency syndromes History of COPD History of pulmonary malignancy or any other malignancy requiring treatment History of prolonged QT syndrome History of hemoptysis Recent significant weight loss Recent use of supplemental oxygen during the day while at rest Recent use of cigarettes, cigars, or pipes, or used tobacco or other nicotine source by vaping Recent changes in either the treatment regimen or initiation of treatment with: oral macrolides, hypertonic saline, mucolytics, bronchodilator medications, or oral corticosteroids Currently receiving treatment for active infection at any site Female pregnant of breastfeeding